title: Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
abstract: OBJECTIVE
  To report a case of worsening of vitreomacular traction (VMT) after the dexamethasone intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).
  
  
  METHODS
  A 71-year-old man who presented with macular edema secondary to CRVO was treated by intravitreal injections of bevacizumab followed by Ozurdex.
  
  
  RESULTS
  VMT developed during the course of treatment and became more evident when macular edema resolved after treatment with Ozurdex.
  
  
  CONCLUSIONS
  VMT may become apparent and worsen after resolution of macular edema treated with intravitreal Ozurdex.
authors.affiliation: Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA. bakri.sophie@mayo.edu
authors.forename: Sophie J
authors.initials: SJ
authors.lastname: Bakri
authors.forename: Ahmed F
authors.initials: AF
authors.lastname: Omar
mesh_terms: D000368:Aged; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004343:Drug Implants; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000187:drug effects* / Q000473:pathology; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D012169:Retinal Vein / Q000473:pathology*; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000473:pathology; D013577:Syndrome; D041623:Tomography, Optical Coherence; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone